연구성과로 돌아가기
2025 연구성과별 연구자 정보 (319 / 1187)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Arai, Yasuaki | Arai, Y | 7 | Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo, Japan | bsangro@unav.es; | |||||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Heo, Jeong | Heo, J | 8 | Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Busan, South Korea | MHQ-1390-2025 | Heo, Jeong | bsangro@unav.es; | |||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Heo, Jeong | Heo, J | 8 | Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea | MHQ-1390-2025 | Heo, Jeong | bsangro@unav.es; | |||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Mai, Anh | Mai, A | 9 | Nhan Dan Gia Dinh Hosp, Gen Surg Dept, Ho Chi Minh City, Vietnam | bsangro@unav.es; | |||||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Escobar, Jose | Escobar, J | 10 | Hosp San Lucas Cardiol Sureste, Chiapas, Mexico | bsangro@unav.es; | |||||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Chuken, Yamil Alonso Lopez | Chuken, YAL | 11 | I Can Oncol Ctr, New Leon, Mexico | bsangro@unav.es; | |||||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Yoon, Jung-Hwan | Yoon, JH | 12 | Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea | J-5563-2012 | Yoon, Jung | bsangro@unav.es; | |||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Yoon, Jung-Hwan | Yoon, JH | 12 | Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea | J-5563-2012 | Yoon, Jung | bsangro@unav.es; | |||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Tak, Won Young | Tak, WY | 13 | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea | bsangro@unav.es; | |||||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Breder, Valeriy V. | Breder, VV | 14 | NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia | bsangro@unav.es; | |||||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Suttichaimongkol, Tanita | Suttichaimongkol, T | 15 | Khon Kaen Univ, Fac Med, Dept Med, Div Gastroenterol & Hepatol, Khon Kaen, Thailand | JDW-6886-2023 | Suttichaimongkol, Tanita | bsangro@unav.es; | |||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Bouattour, Mohamed | Bouattour, M | 16 | Hop Beaujon, AP HP, Liver Canc & Innovat Therapy, Paris, France | bsangro@unav.es; | |||||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Lin, Shi-Ming | Lin, SM | 17 | Chang Gung Mem Hosp, Linkou Med Ctr, Dept Internal Med, Taoyuan, Taiwan | NPI-5122-2025 | Lin, Shiming | bsangro@unav.es; | |||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Peron, Jean-Marie | Peron, JM | 18 | Univ Hosp Purpan, Hepatol Unit, Toulouse, France | bsangro@unav.es; | |||||
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | Nguyen, Quang T. | Nguyen, QT | 19 | Friendship Hosp, Hanoi, Vietnam | LYO-9827-2024 | Nguyen, Quang | bsangro@unav.es; |
페이지 이동: